celecoxib has been researched along with Animal Mammary Carcinoma in 11 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Celecoxib and citrate have been shown to possess antitumor activity in a variety of cancer cells." | 5.42 | Citrate and celecoxib induce apoptosis and decrease necrosis in synergistic manner in canine mammary tumor cells. ( Farsinejad, A; Panahi, N; Safi, S; Vahidi, R, 2015) |
| "We created and characterized a mouse mammary adenocarcinoma cell (MMAC-1) line from C3 (1)-SV40 tumor antigen mice to study COX-2 and PPARgamma expression and response to celecoxib and F-L-Leu in vitro." | 3.74 | Suppression of tumor formation by a cyclooxygenase-2 inhibitor and a peroxisome proliferator-activated receptor gamma agonist in an in vivo mouse model of spontaneous breast cancer. ( Kruger, WD; Mustafa, A, 2008) |
| "Morphine and its congener opioids are the main therapy for severe pain in cancer." | 3.74 | COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia. ( Farooqui, M; Griffin, RJ; Gupta, K; Li, Y; Poonawala, T; Rogers, T; Song, CW, 2007) |
| "Treatment with celecoxib significantly decreased the induced tumor size and metastasis of the PyMT/Col1a1 tumors, such that their size was not different from the smaller PyMT tumors." | 1.43 | COX-2 modulates mammary tumor progression in response to collagen density. ( Esbona, K; Inman, D; Jeffery, J; Keely, P; Saha, S; Schedin, P; Wilke, L, 2016) |
| "Celecoxib plays antitumor roles via multiple mechanisms in a variety of human cancers." | 1.42 | Celecoxib exerts antitumor effects in canine mammary tumor cells via COX‑2‑independent mechanisms. ( Asano, R; Kawashima, M; Murata, K; Saito, T; Tamura, D, 2015) |
| "Celecoxib and citrate have been shown to possess antitumor activity in a variety of cancer cells." | 1.42 | Citrate and celecoxib induce apoptosis and decrease necrosis in synergistic manner in canine mammary tumor cells. ( Farsinejad, A; Panahi, N; Safi, S; Vahidi, R, 2015) |
| "Treatment with celecoxib was examined and compared to treatment with the general NSAID, ibuprofen, and to a control group receiving only dimethylbenz(a)anthracene." | 1.31 | Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. ( Abou-Issa, H; Alshafie, GA; Harris, RE; Seibert, K, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tamura, D | 1 |
| Saito, T | 1 |
| Murata, K | 1 |
| Kawashima, M | 1 |
| Asano, R | 1 |
| Vahidi, R | 1 |
| Safi, S | 1 |
| Farsinejad, A | 1 |
| Panahi, N | 1 |
| Esbona, K | 1 |
| Inman, D | 1 |
| Saha, S | 1 |
| Jeffery, J | 1 |
| Schedin, P | 1 |
| Wilke, L | 1 |
| Keely, P | 1 |
| Negi, AK | 1 |
| Bhatnagar, A | 1 |
| Agnihotri, N | 1 |
| Mustafa, A | 1 |
| Kruger, WD | 1 |
| Shirode, AB | 1 |
| Sylvester, PW | 1 |
| Lubet, RA | 1 |
| Clapper, ML | 1 |
| McCormick, DL | 1 |
| Pereira, MA | 1 |
| Chang, WC | 1 |
| Steele, VE | 1 |
| Fischer, SM | 1 |
| Juliana, MM | 1 |
| Grubbs, CJ | 1 |
| Hahn, T | 1 |
| Alvarez, I | 1 |
| Kobie, JJ | 1 |
| Ramanathapuram, L | 1 |
| Dial, S | 1 |
| Fulton, A | 1 |
| Besselsen, D | 1 |
| Walker, E | 1 |
| Akporiaye, ET | 1 |
| Basu, GD | 1 |
| Tinder, TL | 1 |
| Bradley, JM | 1 |
| Tu, T | 1 |
| Hattrup, CL | 1 |
| Pockaj, BA | 1 |
| Mukherjee, P | 1 |
| Farooqui, M | 1 |
| Li, Y | 1 |
| Rogers, T | 1 |
| Poonawala, T | 1 |
| Griffin, RJ | 1 |
| Song, CW | 1 |
| Gupta, K | 1 |
| Harris, RE | 1 |
| Alshafie, GA | 1 |
| Abou-Issa, H | 1 |
| Seibert, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| IRB-HSR# 13957: IV Lidocaine for Patients Undergoing Primary Breast Cancer Surgery: Effects on Postoperative Recovery and Cancer Recurrence[NCT01204242] | Phase 2 | 78 participants (Actual) | Interventional | 2009-08-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 other studies available for celecoxib and Animal Mammary Carcinoma
| Article | Year |
|---|---|
Celecoxib exerts antitumor effects in canine mammary tumor cells via COX‑2‑independent mechanisms.
Topics: Animals; Antineoplastic Agents; Celecoxib; Cell Cycle; Cell Proliferation; Cyclin-Dependent Kinases; | 2015 |
Citrate and celecoxib induce apoptosis and decrease necrosis in synergistic manner in canine mammary tumor cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cell Sur | 2015 |
COX-2 modulates mammary tumor progression in response to collagen density.
Topics: Animals; Breast Neoplasms; Celecoxib; Cell Line, Tumor; Collagen Type I; Collagen Type I, alpha 1 Ch | 2016 |
Fish oil augments celecoxib mediated alteration in apoptotic pathway in the initiation phase of 7,12-dimethylbenz(α)anthracene-induced mammary carcinogenesis.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Apoptosis; bcl-2-Associated X Protein; Carcinogenesis; Ca | 2016 |
Suppression of tumor formation by a cyclooxygenase-2 inhibitor and a peroxisome proliferator-activated receptor gamma agonist in an in vivo mouse model of spontaneous breast cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cell Line, Tumor | 2008 |
Synergistic anticancer effects of combined gamma-tocotrienol and celecoxib treatment are associated with suppression in Akt and NFkappaB signaling.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cell Line, Tumor; Chromans; Cycl | 2010 |
Chemopreventive efficacy of Targretin in rodent models of urinary bladder, colon/intestine, head and neck and mammary cancers.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Bexarotene; Celecoxib; Co | 2012 |
Short-term dietary administration of celecoxib enhances the efficacy of tumor lysate-pulsed dendritic cell vaccines in treating murine breast cancer.
Topics: Administration, Oral; Animals; Breast Neoplasms; Cancer Vaccines; CD4-Positive T-Lymphocytes; CD8-Po | 2006 |
Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO.
Topics: Adjuvants, Immunologic; Animals; Cancer Vaccines; Celecoxib; Cell Line, Tumor; Cyclooxygenase Inhibi | 2006 |
COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia.
Topics: Analgesia; Analgesics, Opioid; Analysis of Variance; Animals; Behavior, Animal; Blotting, Western; C | 2007 |
Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anticarcinogenic Agents; Body Weight; Celecoxib; Cyclooxy | 2000 |